About Theralytix™

Theralytix was founded in 2020 by entrepreneur and real estate investment speaker Matthew McClellan. Inspired by personal experiences he recognized the urgent need for an alternative to antibiotics. Matthew brought together a team of leading scientists and specialists with expertise in the field of phage therapy.

Since its founding Theralytix has developed seven broad spectrum products that deploy bacteriophages active against multiple strains of pathogenic bacteria in the following genera: Salmonella, Shigella, Pseudomonas, Escherichia, Staphylococcus, Streptococcus, Enterococcus and Proteus.

While Theralytix will initially manufacture branded products for human use, the phage components will be made available to third parties for use in all verticals. With phage cocktails that address eight genera of pathogenic bacteria, Theralytix will lead the pack!